RB1 and central nervous system neoplasm: PBTC-042 was a phase I open-label dose-escalation trial to assess the maximum tolerated dose (MTD) and pharmacokinetics of daily oral PD-0332991 (Palbociclib isethionate) in Rb1+ recurrent, progressive, or refractory primary CNS tumors in young adults (NCT02255461).